Tacti-003: a randomized phase Iib study of eftilagimod alpha (Soluble Lag-3 Protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
Brana, I. Cheshuk, V. Kristensen, C. A. Ortega, M. E. Sautois, B. Lopez-Pousa, A. Christian, J. Lybaert, W. Peguero, J. Park, J.
Brana, I.
Cheshuk, V.
Kristensen, C. A.
Ortega, M. E.
Sautois, B.
Lopez-Pousa, A.
Christian, J.
Lybaert, W.
Peguero, J.
Park, J.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Brana I, Cheshuk V, Kristensen CA, Ortega ME, Sautois B, Lopez-Pousa A, et al. Tacti-003: A Randomized Phase Iib Study of Eftilagimod Alpha (Soluble Lag-3 Protein) and Pembrolizumab as First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Journal for immunotherapy of cancer. 2022 Nov;10:A705-A. PubMed PMID: WOS:000919423400634.